<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biol Open</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol Open</journal-id>
<journal-id journal-id-type="publisher-id">BIO</journal-id>
<journal-id journal-id-type="hwp">biolopen</journal-id>
<journal-title-group>
<journal-title>Biology Open</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-6390</issn>
<publisher>
<publisher-name>The Company of Biologists Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31036753</article-id>
<article-id pub-id-type="pmc">6550086</article-id>
<article-id pub-id-type="doi">10.1242/bio.041327</article-id>
<article-id pub-id-type="publisher-id">BIO041327</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-4032-4355</contrib-id>
<name>
<surname>Kirsten</surname>
<given-names>Thiago B.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1743-5855</contrib-id>
<name>
<surname>Casarin</surname>
<given-names>Renato C.</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6860-9416</contrib-id>
<name>
<surname>Bernardi</surname>
<given-names>Maria M.</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
<xref ref-type="aff" rid="af3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-9068-8317</contrib-id>
<name>
<surname>Felicio</surname>
<given-names>Luciano F.</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label><addr-line>Department of Pathology</addr-line>, <institution>School of Veterinary Medicine, University of São Paulo</institution>, <addr-line>São Paulo 05508-270</addr-line>, <country>Brazil</country></aff>
<aff id="af2"><label>2</label><addr-line>Environmental and Experimental Pathology</addr-line>, <institution>Paulista University</institution>, <addr-line>São Paulo 04026-002</addr-line>, <country>Brazil</country></aff>
<aff id="af3"><label>3</label><addr-line>Graduate Program of Dentistry</addr-line>, <institution>Paulista University</institution>, <addr-line>São Paulo 04026-002</addr-line>, <country>Brazil</country></aff>
<author-notes>
<corresp id="cor1"><label>*</label>Author for correspondence (<email>thik@outlook.com</email>)</corresp>
</author-notes>
<pub-date pub-type="collection">
<day>15</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>4</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>8</volume>
<issue>5</issue>
<elocation-id>bio041327</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019. Published by The Company of Biologists Ltd</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:href="https://creativecommons.org/licenses/by/4.0">https://creativecommons.org/licenses/by/4.0</uri>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="biolopen-8-041327.pdf"></self-uri>
<abstract>
<title>ABSTRACT</title>
<p>We have shown that exposure of rats to lipopolysaccharide (LPS) during gestation induces autistic-like behaviors in juvenile offspring and pioglitazone post treatment corrects social and communication deficits. The first objective of the present study was to evaluate the cognition of the rats, because this is also a behavioral sphere committed in autism. Second, biomarkers related to pioglitazone pathways and autism were studied to try to understand their mechanisms. We used our rat model of autism and pioglitazone was administered daily to these young offspring. T-maze spontaneous alternations tests, plasma levels of brain-derived neurotrophic factor (BDNF), beta-endorphin, neurotensin, oxytocin, and substance P were all studied. Exposure of rats to LPS during gestation induced cognitive deficits in the young offspring, elevated BDNF levels and decreased neurotensin levels. Daily postnatal pioglitazone treatment abolished cognition impairments as well as BDNF and neurotensin disturbances. Together with our previous studies, we suggest pioglitazone as a candidate for the treatment of autism, because it improved the responses of the three most typical autistic-like behaviors. BDNF and neurotensin also appeared to be related to the autistic-like behaviors and should be considered for therapeutic purposes.</p>
</abstract>
<abstract abstract-type="precis">
<p><bold>Summary:</bold> Exposure of rats to lipopolysaccharide during gestation induced autistic-like behaviors in the juvenile offspring. Daily postnatal pioglitazone treatment abolished cognition impairments as well as brain-derived neurotrophic factor and neurotensin disturbances.</p>
</abstract>
<kwd-group>
<title>KEY WORDS</title>
<kwd>Prenatal</kwd>
<kwd>Maternal immune activation</kwd>
<kwd>T-maze spontaneous alternations test</kwd>
<kwd>LPS</kwd>
<kwd>Neuropeptides</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>São Paulo Research Foundation</institution>
<institution-id>http://dx.doi.org/10.13039/501100001807</institution-id>
</institution-wrap>
</funding-source>
<award-id>12/07007-8</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</institution>
<institution-id>http://dx.doi.org/10.13039/501100002322</institution-id>
</institution-wrap>
</funding-source>
<award-id>1029/2014</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>INTRODUCTION</title>
<p>Autism spectrum disorder (ASD) is a developmental disorder that is characterized by social, communicative and cognitive deficits and has a higher prevalence in males (<xref ref-type="bibr" rid="BIO041327C16">DSM-IV, 1994</xref>). The incidence of autism is considered high in the population all over the world: about 1 in 59 children have been identified with ASD (<xref ref-type="bibr" rid="BIO041327C5">Baio et al., 2018</xref>). Although it is considered that the etiology of autism is unknown, genetic and environmental factors (such as prenatal infections and maternal dietary disturbs) have been described as autistic triggers (<xref ref-type="bibr" rid="BIO041327C25">Herbert, 2010</xref>; <xref ref-type="bibr" rid="BIO041327C26">Johnson et al., 2013</xref>; <xref ref-type="bibr" rid="BIO041327C55">Theoharides et al., 2009</xref>).</p>
<p>We have shown that exposure of rats to lipopolysaccharide (LPS, gram-negative bacteria endotoxin) during gestation [gestational day (GD) 9.5] induces socialization and communication deficits as well as repetitive/restricted behavior in juvenile offspring. These behavioral impairments are found just in males and not in the female offspring (<xref ref-type="bibr" rid="BIO041327C31">Kirsten et al., 2010a</xref>, <xref ref-type="bibr" rid="BIO041327C33">2012</xref>; <xref ref-type="bibr" rid="BIO041327C30">Kirsten and Bernardi, 2017</xref>). Therefore, our model of exposure of rats to LPS during gestation induces autistic-like behaviors in juvenile offspring (<xref ref-type="bibr" rid="BIO041327C33">Kirsten et al., 2012</xref>). We have also shown peripheral interleukin (IL)-1 beta and IL-6 levels increase in adult and young male offspring, respectively (<xref ref-type="bibr" rid="BIO041327C34">Kirsten et al., 2013</xref>, <xref ref-type="bibr" rid="BIO041327C37">2018</xref>); results that have been described in autistic patients (<xref ref-type="bibr" rid="BIO041327C41">Li et al., 2009</xref>; <xref ref-type="bibr" rid="BIO041327C27">Jyonouchi et al., 2001</xref>; <xref ref-type="bibr" rid="BIO041327C1">Al-Ayadhi, 2005</xref>). Additionally, the mechanisms that are involved in fetal brain disturbances include the production and release of proinflammatory cytokines within the maternal environment (circulation and placenta) (<xref ref-type="bibr" rid="BIO041327C4">Ashdown et al., 2006</xref>; <xref ref-type="bibr" rid="BIO041327C59">Urakubo et al., 2001</xref>; <xref ref-type="bibr" rid="BIO041327C12">Cai et al., 2000</xref>).</p>
<p>There is no effective treatment for ASD, and a small number of drugs are authorized by the US Food and Drug Administration (FDA) (<xref ref-type="bibr" rid="BIO041327C43">McPheeters et al., 2011</xref>). These drugs have limited efficacy and are able to treat only some ASD symptoms and can trigger adverse effects (<xref ref-type="bibr" rid="BIO041327C62">Wink et al., 2010</xref>). Therefore, the present study proposed to use our rat model of autism to find new pharmacological approaches for autism. Pioglitazone was selected as the postnatal treatment to inhibit or relieve the behavioral and immune disturbances induced after the exposure of rats to LPS during gestation. Pioglitazone belongs to the thiazolidinediones class, which act as peroxisome proliferator-activated receptor gamma (PPARγ) agonists (<xref ref-type="bibr" rid="BIO041327C23">Gillies and Dunn, 2000</xref>; <xref ref-type="bibr" rid="BIO041327C7">Berger and Wagner, 2002</xref>). Pioglitazone is an anti-diabetic drug that is authorized by the FDA to treat type 2 diabetes mellitus (insulin sensitizing effect) (<xref ref-type="bibr" rid="BIO041327C24">Hanefeld and Belcher, 2001</xref>). Besides the anti-diabetic affect, thiazolidinediones has anti-inflammatory properties and has been suggested to treat inflammatory and neurological diseases such as inflammatory bowel disease, psoriasis, atherosclerosis, multiple sclerosis and Alzheimer's (<xref ref-type="bibr" rid="BIO041327C17">Duval et al., 2002</xref>; <xref ref-type="bibr" rid="BIO041327C28">Katayama et al., 2003</xref>; <xref ref-type="bibr" rid="BIO041327C10">Bongartz et al., 2005</xref>; <xref ref-type="bibr" rid="BIO041327C18">Feinstein, 2003</xref>; <xref ref-type="bibr" rid="BIO041327C38">Landreth, 2006</xref>).</p>
<p>There are pilot studies showing that pioglitazone treatment associated with other pharmacological and behavioral therapies induce some clinical improvements in autistic patients. For example, daily pioglitazone treatment attenuated irritability, lethargy, stereotypy and hyperactivity in some autistic children, without significant side effects (<xref ref-type="bibr" rid="BIO041327C11">Boris et al., 2007</xref>). Similarly, pioglitazone potentiated the risperidone effects in ASD patients (<xref ref-type="bibr" rid="BIO041327C20">Ghaleiha et al., 2015</xref>).</p>
<p>Using our rat model of autism, we have demonstrated that pioglitazone treatment corrects social and communication deficits as well as elevated plasma IL-6 levels (<xref ref-type="bibr" rid="BIO041327C37">Kirsten et al., 2018</xref>). The first objective of the present study was to evaluate the cognition of the rats, because this is also a behavioral sphere committed in autism. Second, biomarkers related to pioglitazone pathways and ASD were studied to try to understand their mechanisms.</p>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<p><xref ref-type="fig" rid="BIO041327F1">Fig. 1</xref> shows the effects of prenatal LPS and postnatal pioglitazone exposure on the T-maze spontaneous alternation test of the rats. The performance in the T-maze task was different between groups (KW=13.48, <italic>P</italic>=0.0037). Prenatal LPS exposure decreased T-maze spontaneous alternation in the offspring compared with the control group (<italic>P</italic>&lt;0.01). Although postnatal pioglitazone treatment with 0.25 mg/kg/day did not affect the performance in the T-maze task, postnatal pioglitazone treatment with 1.0 mg/kg/day increased spontaneous alternation in the rats prenatally exposed to LPS (LPS+PI1.0 group versus LPS+DMSO group, <italic>P</italic>&lt;0.05) to the same levels as those in the control group. Thus, prenatal LPS induced cognitive inflexibility, and postnatal pioglitazone treatment abolished these impairments.
<fig id="BIO041327F1" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p><bold>T-maze.</bold> The effects of prenatal LPS (100 µg/kg at GD 9.5) and postnatal pioglitazone [0.25 and 1.0 mg/kg/day between postnatal days (PND) 21 and 29] exposures on the T-maze spontaneous alternation test in juvenile male rat offspring. SAL+DMSO, prenatal saline injection and postnatal daily DMSO injection; LPS+DMSO, prenatal LPS injection and postnatal daily DMSO injection; LPS+PI0.25, prenatal LPS injection and postnatal pioglitazone 0.25 mg/kg/day; LPS+PI1.0, prenatal LPS injection and postnatal pioglitazone 1.0 mg/kg/day (<italic>n</italic>=8 rats/group). *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01 (Kruskal–Wallis test followed by Dunn's test). The data are expressed as the median (minimum and maximum).</p></caption><graphic xlink:href="biolopen-8-041327-g1"></graphic></fig></p>
<p><xref ref-type="fig" rid="BIO041327F2">Fig. 2</xref> shows the effects of prenatal LPS and postnatal pioglitazone exposure on the total BDNF plasma levels of the rats. The BDNF levels were affected by the treatments [<italic>F</italic>(3/28)=5.43, <italic>P</italic>=0.0045]. Prenatal LPS exposure (LPS+DMSO group) increased the total BDNF levels compared with the control group (SAL+DMSO, <italic>P</italic>&lt;0.001). Both doses (0.25 and 1.0 mg/kg/day) of the post-treatment with pioglitazone decreased BDNF levels in the rats that were prenatally exposed to LPS (versus LPS+DMSO group, <italic>P</italic>&lt;0.05 for both doses) to the same levels as those in the control group.
<fig id="BIO041327F2" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p><bold>BDNF.</bold> The effects of prenatal LPS (100 µg/kg at GD 9.5) and postnatal pioglitazone (0.25 and 1.0 mg/kg/day between PND 21 and 29) exposures on the total BDNF plasma levels in juvenile male rat offspring. SAL+DMSO, prenatal saline injection and postnatal daily DMSO injection; LPS+DMSO, prenatal LPS injection and postnatal daily DMSO injection; LPS+PI0.25, prenatal LPS injection and postnatal pioglitazone 0.25 mg/kg/day; LPS+PI1.0, prenatal LPS injection and postnatal pioglitazone 1.0 mg/kg/day (<italic>n</italic>=8 rats/group). *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001 (one-way ANOVA followed by the Fisher's LSD test). The data are expressed as the mean±s.e.m.</p></caption><graphic xlink:href="biolopen-8-041327-g2"></graphic></fig></p>
<p><xref ref-type="fig" rid="BIO041327F3">Fig. 3</xref> shows the effects of prenatal LPS and postnatal pioglitazone exposure on the beta-endorphin, neurotensin, oxytocin and substance P plasma levels of the rats. Both beta-endorphin and neurotensin levels were affected by the treatments [<italic>F</italic>(3/28)=3.15, <italic>P</italic>=0.0407 and <italic>F</italic>(3/28)=8.41, <italic>P</italic>=0.0004, respectively], whereas oxytocin and substance P levels were not affected by the treatments [<italic>F</italic>(3/28)=2.34, <italic>P</italic>=0.0944 and <italic>F</italic>(3/28)=2.58, <italic>P</italic>=0.0735, respectively]. Prenatal LPS exposure (LPS+DMSO group) did not affect beta-endorphin levels compared with the control group (SAL+DMSO). Both pioglitazone doses (LPS+PI0.25 and LPS+PI1.0 groups) increased the beta-endorphin levels compared with the LPS group (versus LPS+DMSO, <italic>P</italic>&lt;0.05 and <italic>P</italic>&lt;0.01, respectively). Prenatal LPS exposure increased neurotensin levels compared with the control group (SAL+DMSO, <italic>P</italic>&lt;0.01). Although postnatal pioglitazone treatment with 0.25 mg/kg/day did not affect the neurotensin levels compared with the LPS group it recovered the levels to the same levels as those in the control group. Postnatal pioglitazone treatment with 1.0 mg/kg/day increased the neurotensin levels in the rats prenatally exposed to LPS (LPS+PI1.0 group versus LPS+DMSO group, <italic>P</italic>&lt;0.0001) to the same levels as those in the control group. Thus, prenatal LPS decreased neurotensin levels, and postnatal pioglitazone treatment recovered this disturbance.
<fig id="BIO041327F3" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p><bold>Neuropeptides.</bold> The effects of prenatal LPS (100 μg/kg at GD 9.5) and postnatal pioglitazone (0.25 and 1.0 mg/kg/day between PND 21 and 29) exposures on beta-endorphin, neurotensin, oxytocin and substance P plasma levels in juvenile male rat offspring. SAL+DMSO, prenatal saline injection and postnatal daily DMSO injection; LPS+DMSO, prenatal LPS injection and postnatal daily DMSO injection; LPS+PI0.25, prenatal LPS injection and postnatal pioglitazone 0.25 mg/kg/day; LPS+PI1.0, prenatal LPS injection and postnatal pioglitazone 1.0 mg/kg/day (<italic>n</italic>=8 rats/group). *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001, ****<italic>P</italic>&lt;0.0001 (one-way ANOVA followed by the Fisher's LSD test). The data are expressed as the mean±s.e.m.</p></caption><graphic xlink:href="biolopen-8-041327-g3"></graphic></fig></p>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>The most typical symptoms found in ASD are social, communicative and cognitive deficits, such as cognitive inﬂexibility and repetitive/restricted behavior (<xref ref-type="bibr" rid="BIO041327C16">DSM-IV, 1994</xref>). We have shown that exposure of rats to LPS during gestation impairs communication in terms of ultrasonic vocalization (40 and 50 kHz), socialization (play behavior), induces repetitive/restricted behavior in terms of self-grooming and cognitive inﬂexibility (T-maze) in male offspring (<xref ref-type="bibr" rid="BIO041327C31">Kirsten et al., 2010a</xref>, <xref ref-type="bibr" rid="BIO041327C33">2012</xref>, <xref ref-type="bibr" rid="BIO041327C35">2015a</xref>,<xref ref-type="bibr" rid="BIO041327C36">b</xref>; <xref ref-type="bibr" rid="BIO041327C30">Kirsten and Bernardi, 2017</xref>). Therefore, our model of exposure of rats to LPS during gestation induces autistic-like behaviors in juvenile offspring.</p>
<p>Considering no effective treatment yet exists for autism, we started to search for new treatments for autistic symptoms using our rat model. We selected pioglitazone because although it is originally an anti-diabetic drug, it also exerts anti-inflammatory effects in several cell types (<xref ref-type="bibr" rid="BIO041327C7">Berger and Wagner, 2002</xref>; <xref ref-type="bibr" rid="BIO041327C24">Hanefeld and Belcher, 2001</xref>). Moreover, there are pilot studies showing that pioglitazone treatment associated with other pharmacological and behavioral therapies induces some clinical improvements in autistic patients (<xref ref-type="bibr" rid="BIO041327C11">Boris et al., 2007</xref>).</p>
<p>We have demonstrated that pioglitazone treatment corrects social and communication deficits (<xref ref-type="bibr" rid="BIO041327C37">Kirsten et al., 2018</xref>). Our present results revealed that postnatal pioglitazone treatment with 1.0 mg/kg/day abolished the decreased T-maze spontaneous alternation induced by prenatal LPS. Together with our previous study (<xref ref-type="bibr" rid="BIO041327C37">Kirsten et al., 2018</xref>), we suggest pioglitazone as a candidate for the treatment of autism, since it improved the responses of the three most typical autistic-like behaviors.</p>
<p>BDNF is a member of the neurotrophins family and is found in the central nervous system and peripheral blood. It is involved with morphological, developmental and neuronal processes, such as synaptogenesis and synaptic plasticity (<xref ref-type="bibr" rid="BIO041327C8">Binder and Scharfman, 2004</xref>). Several autistic patients present elevated serum (<xref ref-type="bibr" rid="BIO041327C53">Ricci et al., 2013</xref>), plasma (<xref ref-type="bibr" rid="BIO041327C14">Correia et al., 2010</xref>), postmortem brain (<xref ref-type="bibr" rid="BIO041327C19">Garcia et al., 2012</xref>) and neonatal cord blood (<xref ref-type="bibr" rid="BIO041327C46">Nelson et al., 2001</xref>) levels of BDNF. Exposure of rats to LPS during gestation increased BDNF plasma levels. Thus, our rat model of autism also successfully reproduced the BDNF disturbance found in patients.</p>
<p>Both doses of postnatal pioglitazone treatment (0.25 and 1.0 mg/kg/day) abolished the BDNF disturbance induced by prenatal LPS. Although there are few studies about the relation between pioglitazone and BDNF, it is known that memory impairment, BDNF disturbance and oxidative damage induced by β-amyloid in an animal model of Alzheimer's disease are reversed by chronic administration of pioglitazone (<xref ref-type="bibr" rid="BIO041327C50">Prakash and Kumar, 2014</xref>). Moreover, just like pioglitazone, BDNF has an anti-diabetic effect, ameliorating glucose metabolism and pancreatic dysfunction in type 2 diabetic mice (<xref ref-type="bibr" rid="BIO041327C64">Yamanaka et al., 2007</xref>). Therefore, the BDNF disturbance induced by prenatal LPS was abolished by pioglitazone treatment.</p>
<p>Beta-endorphin, neurotensin, oxytocin and substance P plasma levels were studied because of their relationship with autism. There are reports of increased (<xref ref-type="bibr" rid="BIO041327C56">Tordjman et al., 2009</xref>), decreased (<xref ref-type="bibr" rid="BIO041327C22">Gillberg, 1992</xref>; <xref ref-type="bibr" rid="BIO041327C61">Weizman et al., 1988</xref>) and unaltered (<xref ref-type="bibr" rid="BIO041327C3">Angelidou et al., 2010</xref>) plasma/serum levels of beta-endorphin in autistic patients. Neurotensin levels have been found to be increased in the sera of 3-year old (<xref ref-type="bibr" rid="BIO041327C3">Angelidou et al., 2010</xref>) and 6–12 year-old children with autism (<xref ref-type="bibr" rid="BIO041327C58">Tsilioni et al., 2014</xref>). There are several studies reporting that ASD could be a result of oxytocin system disturbances early in life (<xref ref-type="bibr" rid="BIO041327C51">Quattrocki and Friston, 2014</xref>). Oxytocin levels have been found to be decreased in the saliva of adolescent boys with autism (<xref ref-type="bibr" rid="BIO041327C6">Bakker-Huvenaars et al., 2018</xref>), as well as in the plasma of Chinese autistic patients (<xref ref-type="bibr" rid="BIO041327C67">Zhang et al., 2016</xref>). However, another group of autistic children and adolescents exhibited elevated serum oxytocin levels (<xref ref-type="bibr" rid="BIO041327C65">Yang et al., 2017</xref>). Finally, substance P is also considered a possible factor in ASD because it is a product of the <italic>Tachykinin 1</italic> gene (<italic>TAC1</italic>), which is located in a candidate region for ASD (<xref ref-type="bibr" rid="BIO041327C42">Marui et al., 2007</xref>). However, both serum (<xref ref-type="bibr" rid="BIO041327C3">Angelidou et al., 2010</xref>) and neonatal blood (<xref ref-type="bibr" rid="BIO041327C46">Nelson et al., 2001</xref>) of children with ASD present similar levels of substance P compared with control subject levels.</p>
<p>The apparent contradictory findings in the literature about the relationship between neuropeptides and autism may be explained by the presumably multifactorial etiopathogenesis of autism. Autism may be a result from a complex interaction between genetic and environmental factors (<xref ref-type="bibr" rid="BIO041327C49">Posar and Visconti, 2017</xref>). Possible triggers include several chromosomal and gene disturbances, air pollutants, pesticides and other endocrine-disrupting chemicals, prenatal infections, mitochondrial dysfunction, electromagnetic pollution, diet modifications and possible epigenetic mechanisms (<xref ref-type="bibr" rid="BIO041327C49">Posar and Visconti, 2017</xref>; <xref ref-type="bibr" rid="BIO041327C57">Tordjman et al., 2014</xref>; <xref ref-type="bibr" rid="BIO041327C39">Landrigan, 2010</xref>; <xref ref-type="bibr" rid="BIO041327C40">Larsson et al., 2005</xref>).</p>
<p>Apparently, prenatal LPS exposure did not affect beta-endorphin, oxytocin and substance P plasma levels. Thus, the induction of autistic-like effects after the exposure of rats to LPS during gestation does not appear to be related to these neuropeptide pathways. However, prenatal LPS decreased neurotensin levels and postnatal pioglitazone treatment with 1.0 mg/kg/day abolished this disturbance.</p>
<p>There are a few studies about neurotensin and autism, and they report that autism increases neurotensin serum levels in children with autism (<xref ref-type="bibr" rid="BIO041327C3">Angelidou et al., 2010</xref>; <xref ref-type="bibr" rid="BIO041327C58">Tsilioni et al., 2014</xref>). We would expect that prenatal LPS should increase neurotensin levels because neurotensin may act like a neurotoxic factor and stimulating microglia, which activates the mammalian target of rapamycin (mTOR) signaling kinase and stimulates IL-1 beta gene expression (<xref ref-type="bibr" rid="BIO041327C48">Patel et al., 2016</xref>; <xref ref-type="bibr" rid="BIO041327C21">Ghanizadeh, 2010</xref>). Speaking of which, we have shown that prenatal LPS increases both striatal mTOR (<xref ref-type="bibr" rid="BIO041327C35">Kirsten et al., 2015a</xref>) and serum IL-1 beta (<xref ref-type="bibr" rid="BIO041327C34">Kirsten et al., 2013</xref>) levels in rats.</p>
<p>Neurotensin is widely distributed in the nervous system and peripherally, with neurotransmitter or neuromodulator roles (<xref ref-type="bibr" rid="BIO041327C60">Vincent et al., 1999</xref>), including for cognition (<xref ref-type="bibr" rid="BIO041327C15">Dobner, 2005</xref>). PD149163 administration, which is a neurotensin NTS1-receptor agonist, improves memory performance in Norway rats (<xref ref-type="bibr" rid="BIO041327C29">Keiser et al., 2014</xref>). It is also described that activation of neurotensin receptor 1 has beneficial actions in a mouse model of Alzheimer's disease (<xref ref-type="bibr" rid="BIO041327C63">Xiao et al., 2014</xref>). Considering that neurotensin activation is involved in cognition improvement, it seems reasonable to understand our findings of prenatal LPS reducing neurotensin levels and consequently impairing behavioral parameters of cognition (T-maze).</p>
<p>Moreover, the neurotensin reduction after prenatal LPS may be related to a dopaminergic disturbance. We previously reported that our rat model induces striatal dopaminergic disturbances in the offspring, such as decreased tyrosine hydroxylase expression as well as dopamine and metabolite level reduction (<xref ref-type="bibr" rid="BIO041327C33">Kirsten et al., 2012</xref>, <xref ref-type="bibr" rid="BIO041327C32">2010b</xref>) as well as dopaminergic hypoactivity in the hypothalamus (<xref ref-type="bibr" rid="BIO041327C30">Kirsten and Bernardi, 2017</xref>). Experimental evidence indicates intimate anatomical and biochemical relationships between the neurotensinergic and the dopaminergic systems (<xref ref-type="bibr" rid="BIO041327C9">Binder et al., 2001</xref>; <xref ref-type="bibr" rid="BIO041327C54">Rodríguez de Lores Arnaiz and Antonelli, 2016</xref>). Neurotensin and dopaminergic neurons are strongly co-located, and its receptors are expressed on both the dopaminergic neurons and on their postsynaptic targets (<xref ref-type="bibr" rid="BIO041327C45">Muehlmann et al., 2018</xref>). Therefore, the neurotensin disturbance induced by prenatal LPS occurred possibly in response to the central dopaminergic impairment.</p>
<p>Future studies focusing on the central nervous system, especially for brain neurotensin levels and NTS1 and NTR3/sortilin receptors would be interesting for a better understanding of the mechanisms involved with ASD and neurotensin, including as a potential therapeutic target for autism.</p>
<p>In conclusion, exposure of rats to LPS during gestation (GD 9.5) induced cognitive inflexibility and elevated BDNF levels in juvenile male rat offspring, which are described as autistic-like symptoms. We also found reduced plasma neurotensin levels after prenatal LPS exposure. Daily postnatal pioglitazone treatment corrected the cognition impairments, as well as BDNF and neurotensin disturbances. Together with our previous studies (<xref ref-type="bibr" rid="BIO041327C37">Kirsten et al., 2018</xref>), we suggested pioglitazone as a candidate for the treatment of autism, because it improved the responses of the three most typical autistic-like behaviors. BDNF and neurotensin also appeared to be related with autistic-like behaviors and should be considered for therapeutic purposes.</p>
</sec>
<sec id="s4" sec-type="methods">
<title>MATERIALS AND METHODS</title>
<sec id="s4a">
<title>Ethics statement</title>
<p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the School of Veterinary Medicine, University of São Paulo, Brazil (permit no. 2824/2012). All efforts were made to minimize the suffering, reduce the number of animals used and utilize alternatives to <italic>in vivo</italic> techniques when available. The experiments were performed in accordance with good laboratory practice protocols and quality assurance methods.</p>
</sec>
<sec id="s4b">
<title>Animals</title>
<p>Nineteen pregnant Wistar rats (<italic>Rattus norvegicus</italic>) of 15–17 weeks of age and weighing 220–275 g were used. The rats’ housing, nutritional conditions, determination of GD 0, pregnancy monitoring, weaning and litter sexing during the experiments were the same as previously described by our group (<xref ref-type="bibr" rid="BIO041327C33">Kirsten et al., 2012</xref>, <xref ref-type="bibr" rid="BIO041327C37">2018</xref>).</p>
</sec>
<sec id="s4c">
<title>Prenatal treatments</title>
<p>LPS (from <italic>Escherichia coli</italic>; Sigma-Aldrich; serotype 0127: B8) was dissolved in sterile saline (50 µg/ml LPS in a 0.9% NaCl solution) and administered intraperitoneally (i.p.) to pregnant dams at a dose of 100 µg/kg on GD 9.5 (<italic>n</italic>=13). This GD of LPS exposure as well as the dose was chosen based on our previous studies (<xref ref-type="bibr" rid="BIO041327C31">Kirsten et al., 2010a</xref>,<xref ref-type="bibr" rid="BIO041327C32">b</xref>, <xref ref-type="bibr" rid="BIO041327C34">2013</xref>). Other dams received the vehicle (0.9% sterile saline, SAL) on GD 9.5 (<italic>n</italic>=6). Each dam (LPS and control) received 0.2 ml/100 g of each solution (LPS and vehicle solutions).</p>
</sec>
<sec id="s4d">
<title>Postnatal treatments and groups</title>
<p>The male offspring which were prenatally exposed to LPS (or SAL) also received pioglitazone (Sigma-Aldrich) or its vehicle dimethyl sulfoxide (DMSO, diluted to 1:10 in SAL) daily from PND 21 until 29. Rats received one of two pioglitazone doses: 0.25 and 1.0 mg/kg/day (i.p.) based on the pharmacokinetics of the drug (Actos, Abbott, Rio de Janeiro, Brazil), the autistic children's prescriptions (<xref ref-type="bibr" rid="BIO041327C11">Boris et al., 2007</xref>) and rat studies (<xref ref-type="bibr" rid="BIO041327C47">Park et al., 2007</xref>; <xref ref-type="bibr" rid="BIO041327C66">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="BIO041327C2">Alzamendi et al., 2012</xref>). The prepubertal period of the daily treatment was also based on an autistic children’s study (<xref ref-type="bibr" rid="BIO041327C11">Boris et al., 2007</xref>) and the equivalent age between humans and rats (<xref ref-type="bibr" rid="BIO041327C52">Quinn, 2005</xref>).</p>
<p>Four groups were investigated (<italic>n</italic>=8 rats per group): the SAL+DMSO group (control group), the LPS+DMSO group (LPS group), the LPS+PI0.25 group and the LPS+PI1.0 group. The experimental groups are described in <xref ref-type="table" rid="BIO041327TB1">Table 1</xref>.<table-wrap id="BIO041327TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p><bold>Experimental groups</bold></p></caption><graphic xlink:href="biolopen-8-041327-i1"></graphic></table-wrap></p>
</sec>
<sec id="s4e">
<title>T-maze</title>
<p>One of the most typical symptoms of ASD is cognitive inflexibility (<xref ref-type="bibr" rid="BIO041327C16">DSM-IV, 1994</xref>). To evaluate cognitive inflexibility, we used a T-maze; the T-maze specifications and behavioral protocol that were used during the experiments were the same as previously described by our group (<xref ref-type="bibr" rid="BIO041327C35">Kirsten et al., 2015a</xref>; <xref ref-type="bibr" rid="BIO041327C13">Cezar et al., 2018</xref>). The parameter analyzed was the alternation between the left and right arms after the five sessions. These data were transformed into scores: 0–4, i.e., from no alternations to four alternations.</p>
</sec>
<sec id="s4f">
<title>Plasma evaluations</title>
<p>On PND 36–40, the rats that were previously evaluated for their behavior were decapitated and plasma samples were obtained as previously described by our group (<xref ref-type="bibr" rid="BIO041327C44">Moraes et al., 2017</xref>). BDNF (cat. no. G7610, Promega) analysis was performed using commercial enzyme-linked immunosorbent assay kits. Neuropeptides analysis, which included the analysis of beta-endorphin, neurotensin, oxytocin and substance P, was performed using Luminex/Magpix/Milliplex system (cat. no. RMNPMAG-83K, Millipore).</p>
</sec>
<sec id="s4g">
<title>Statistical analysis</title>
<p>Homogeneity and normality were verified using a Bartlett's test or <italic>F</italic> test. For the T-maze score analysis, a Kruskal–Wallis test was used, followed by a Dunn's test. One-way analysis of variance (ANOVA) followed by Fisher's LSD multiple comparison tests were used to compare the parametric data between the four groups. The results are expressed as the median (minimum and maximum) or the mean±s.e.m. In all cases, the results were considered as statistically signiﬁcant at <italic>P</italic>&lt;0.05.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors are grateful to Dr Nicolle Queiroz-Hazarbassanov for the support in the BDNF ELISA analyses.</p>
</ack>
<fn-group>
<title>Footnotes</title>
<fn fn-type="COI-statement">
<p>
<bold>Competing interests</bold>
</p>
<p>The authors declare no competing or financial interests.</p>
</fn>
<fn>
<p>
<bold>Author contributions</bold>
</p>
<p>Conceptualization: T.B.K., M.M.B., L.F.F.; Methodology: T.B.K., R.C.C.; Validation: T.B.K.; Formal analysis: T.B.K., R.C.C.; Investigation: T.B.K.; Resources: T.B.K., M.M.B.; Data curation: T.B.K.; Writing - original draft: T.B.K.; Writing - review &amp; editing: T.B.K., R.C.C., M.M.B., L.F.F.; Visualization: T.B.K., R.C.C., M.M.B., L.F.F.; Supervision: L.F.F.; Project administration: T.B.K.; Funding acquisition: T.B.K., M.M.B.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>
<bold>Funding</bold>
</p>
<p>This research was supported by the São Paulo Research Foundation (FAPESP grant no. 12/07007-8) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/Prêmio 1029/2014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="BIO041327C1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ayadhi</surname><given-names>L. Y.</given-names></name></person-group> (<year>2005</year>). <article-title>Pro-inflammatory cytokines in autistic children in central Saudi Arabia</article-title>. <source/><italic toggle="yes">Neurosciences (Riyadh)</italic>
<volume>10</volume>, <fpage>155</fpage>-<lpage>158</lpage>.<pub-id pub-id-type="pmid">22473229</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alzamendi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Giovambattista</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>García</surname><given-names>M. E.</given-names></name>, <name name-style="western"><surname>Rebolledo</surname><given-names>O. R.</given-names></name>, <name name-style="western"><surname>Gagliardino</surname><given-names>J. J.</given-names></name> and <name name-style="western"><surname>Spinedi</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Effect of pioglitazone on the fructose-induced abdominal adipose tissue dysfunction</article-title>. <source/><italic toggle="yes">PPAR Res.</italic>
<volume>2012</volume>, <fpage>259093</fpage>
<pub-id pub-id-type="doi">10.1155/2012/259093</pub-id><pub-id pub-id-type="pmid">23091482</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelidou</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Francis</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Vasiadi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Alysandratos</surname><given-names>K.-D.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Theoharides</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lykouras</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Sideri</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kalogeromitros</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Neurotensin is increased in serum of young children with autistic disorder</article-title>. <source/><italic toggle="yes">J. Neuroinflammation</italic>
<volume>7</volume>, <fpage>48</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-7-48</pub-id><pub-id pub-id-type="pmid">20731814</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashdown</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Dumont</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Poole</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Boksa</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Luheshi</surname><given-names>G. N.</given-names></name></person-group> (<year>2006</year>). <article-title>The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia</article-title>. <source/><italic toggle="yes">Mol. Psychiatry</italic>
<volume>11</volume>, <fpage>47</fpage>-<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001748</pub-id><pub-id pub-id-type="pmid">16189509</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baio</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wiggins</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Christensen</surname><given-names>D. L.</given-names></name>, <name name-style="western"><surname>Maenner</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Daniels</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Kurzius-Spencer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zahorodny</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014</article-title>. <source/><italic toggle="yes">MMWR Surveill. Summ.</italic>
<volume>67</volume>, <fpage>1</fpage>-<lpage>23</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.ss6706a1</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakker-Huvenaars</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Greven</surname><given-names>C. U.</given-names></name>, <name name-style="western"><surname>Herpers</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Wiegers</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Jansen</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Van Der Steen</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>van Herwaarden</surname><given-names>A. E.</given-names></name>, <name name-style="western"><surname>Baanders</surname><given-names>A. N.</given-names></name>, <name name-style="western"><surname>Nijhof</surname><given-names>K. S.</given-names></name>, <name name-style="western"><surname>Scheepers</surname><given-names>F.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>). <article-title>Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals</article-title>. <source/><italic toggle="yes">Eur. Neuropsychopharmacol.</italic>
<volume>S0924-977X</volume>, <fpage>30280</fpage>-<lpage>30283</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2018.07.097</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Wagner</surname><given-names>J. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Physiological and therapeutic roles of peroxisome proliferator-activated receptors</article-title>. <source/><italic toggle="yes">Diabetes Technol. Ther.</italic>
<volume>4</volume>, <fpage>163</fpage>-<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1089/15209150260007381</pub-id><pub-id pub-id-type="pmid">12079620</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>D. K.</given-names></name> and <name name-style="western"><surname>Scharfman</surname><given-names>H. E.</given-names></name></person-group> (<year>2004</year>). <article-title>Mini Review</article-title>. <source/><italic toggle="yes">Growth Factors</italic>
<volume>22</volume>, <fpage>123</fpage>-<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1080/08977190410001723308</pub-id><pub-id pub-id-type="pmid">15518235</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>E. B.</given-names></name>, <name name-style="western"><surname>Kinkead</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Owens</surname><given-names>M. J.</given-names></name> and <name name-style="western"><surname>Nemeroff</surname><given-names>C. B.</given-names></name></person-group> (<year>2001</year>). <article-title>Neurotensin and dopamine interactions</article-title>. <source/><italic toggle="yes">Pharmacol. Rev.</italic>
<volume>53</volume>, <fpage>453</fpage>-<lpage>486</lpage>.<pub-id pub-id-type="pmid">11734615</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bongartz</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Coras</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Vogt</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Scholmerich</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Muller-Ladner</surname><given-names>U.</given-names></name></person-group> (<year>2005</year>). <article-title>Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study</article-title>. <source/><italic toggle="yes">Rheumatology (Oxf.)</italic>
<volume>44</volume>, <fpage>126</fpage>-<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keh423</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boris</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kaiser</surname><given-names>C. C.</given-names></name>, <name name-style="western"><surname>Goldblatt</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Elice</surname><given-names>M. W.</given-names></name>, <name name-style="western"><surname>Edelson</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>J. B.</given-names></name> and <name name-style="western"><surname>Feinstein</surname><given-names>D. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Effect of pioglitazone treatment on behavioral symptoms in autistic children</article-title>. <source/><italic toggle="yes">J. Neuroinflammation</italic>
<volume>4</volume>, <fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-4-3</pub-id><pub-id pub-id-type="pmid">17207275</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>Z.-L.</given-names></name>, <name name-style="western"><surname>Pang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>O. B.</given-names></name> and <name name-style="western"><surname>Rhodes</surname><given-names>P. G.</given-names></name></person-group> (<year>2000</year>). <article-title>Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration</article-title>. <source/><italic toggle="yes">Pediatr. Res.</italic>
<volume>47</volume>, <fpage>64</fpage>-<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1203/00006450-200001000-00013</pub-id><pub-id pub-id-type="pmid">10625084</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cezar</surname><given-names>L. C.</given-names></name>, <name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Da Fonseca</surname><given-names>C. C. N.</given-names></name>, <name name-style="western"><surname>De Lima</surname><given-names>A. P. N.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name> and <name name-style="western"><surname>Felicio</surname><given-names>L. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Zinc as a therapy in a rat model of autism prenatally induced by valproic acid</article-title>. <source/><italic toggle="yes">Prog. Neuropsychopharmacol. Biol. Psychiatry</italic>
<volume>84</volume>, <fpage>173</fpage>-<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.02.008</pub-id><pub-id pub-id-type="pmid">29481896</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correia</surname><given-names>C. T.</given-names></name>, <name name-style="western"><surname>Coutinho</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Sequeira</surname><given-names>A. F.</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>I. G.</given-names></name>, <name name-style="western"><surname>Lourenço Venda</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Almeida</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Abreu</surname><given-names>R. L.</given-names></name>, <name name-style="western"><surname>Lobo</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Miguel</surname><given-names>T. S.</given-names></name>, <name name-style="western"><surname>Conroy</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>). <article-title>Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism</article-title>. <source/><italic toggle="yes">Genes Brain Behav.</italic>
<volume>9</volume>, <fpage>841</fpage>-<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2010.00627.x</pub-id><pub-id pub-id-type="pmid">20662941</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobner</surname><given-names>P. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Multitasking with neurotensin in the central nervous system</article-title>. <source/><italic toggle="yes">Cell. Mol. Life Sci.</italic>
<volume>62</volume>, <fpage>1946</fpage>-<lpage>1963</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-005-5128-x</pub-id><pub-id pub-id-type="pmid">16003489</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C16">
<mixed-citation publication-type="book"><collab>DSM-IV</collab>. (<year>1994</year>). <source/><italic toggle="yes">Pervasive Developmental Disorders</italic>, <edition>4th edn.</edition>, pp. <fpage>65</fpage>-<lpage>78</lpage>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</mixed-citation>
</ref>
<ref id="BIO041327C17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duval</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chinetti</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Trottein</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Fruchart</surname><given-names>J.-C.</given-names></name> and <name name-style="western"><surname>Staels</surname><given-names>B.</given-names></name></person-group> (<year>2002</year>). <article-title>The role of PPARs in atherosclerosis</article-title>. <source/><italic toggle="yes">Trends Mol. Med.</italic>
<volume>8</volume>, <fpage>422</fpage>-<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1016/S1471-4914(02)02385-7</pub-id><pub-id pub-id-type="pmid">12223313</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinstein</surname><given-names>D. L.</given-names></name></person-group> (<year>2003</year>). <article-title>Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease</article-title>. <source/><italic toggle="yes">Diabetes Technol. Ther.</italic>
<volume>5</volume>, <fpage>67</fpage>-<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1089/152091503763816481</pub-id><pub-id pub-id-type="pmid">12725709</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>K. L. P.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Nicolini</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Michalski</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Garzon</surname><given-names>D. J.</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>V. S.</given-names></name>, <name name-style="western"><surname>Tongiorgi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Szatmari</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Fahnestock</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism</article-title>. <source/><italic toggle="yes">J. Neuropathol. Exp. Neurol.</italic>
<volume>71</volume>, <fpage>289</fpage>-<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0b013e31824b27e4</pub-id><pub-id pub-id-type="pmid">22437340</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaleiha</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Rasa</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Nikoo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Farokhnia</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mohammadi</surname><given-names>M.-R.</given-names></name> and <name name-style="western"><surname>Akhondzadeh</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism</article-title>. <source/><italic toggle="yes">Psychiatry Res.</italic>
<volume>229</volume>, <fpage>181</fpage>-<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2015.07.043</pub-id><pub-id pub-id-type="pmid">26208985</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghanizadeh</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Targeting neurotensin as a potential novel approach for the treatment of autism</article-title>. <source/><italic toggle="yes">J. Neuroinflammation</italic>
<volume>7</volume>, <fpage>58</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-7-58</pub-id><pub-id pub-id-type="pmid">20920308</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillberg</surname><given-names>C.</given-names></name></person-group> (<year>1992</year>). <article-title>Plasma beta-endorphin concentrations in autism</article-title>. <source/><italic toggle="yes">J. Autism Dev. Disord.</italic>
<volume>22</volume>, <fpage>131</fpage>-<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1007/BF01046409</pub-id><pub-id pub-id-type="pmid">1592763</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillies</surname><given-names>P. S.</given-names></name> and <name name-style="western"><surname>Dunn</surname><given-names>C. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Pioglitazone</article-title>. <source/><italic toggle="yes">Drugs</italic>
<volume>60</volume>, <fpage>333</fpage>-<lpage>343</lpage>; <comment>discussion 44-45</comment>
<pub-id pub-id-type="doi">10.2165/00003495-200060020-00009</pub-id><pub-id pub-id-type="pmid">10983737</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanefeld</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Belcher</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Safety profile of pioglitazone</article-title>. <source/><italic toggle="yes">Int. J. Clin. Pract. Suppl.</italic>
<volume>121</volume>, <fpage>27</fpage>-<lpage>31</lpage>.</mixed-citation>
</ref>
<ref id="BIO041327C25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbert</surname><given-names>M. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders</article-title>. <source/><italic toggle="yes">Curr. Opin. Neurol.</italic>
<volume>23</volume>, <fpage>103</fpage>-<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e328336a01f</pub-id><pub-id pub-id-type="pmid">20087183</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>N. L.</given-names></name>, <name name-style="western"><surname>Giarelli</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Rice</surname><given-names>C. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Genomics and autism spectrum disorder</article-title>. <source/><italic toggle="yes">J. Nurs. Scholarsh.</italic>
<volume>45</volume>, <fpage>69</fpage>-<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1111/j.1547-5069.2012.01483.x</pub-id><pub-id pub-id-type="pmid">23368711</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jyonouchi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Le</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression</article-title>. <source/><italic toggle="yes">J. Neuroimmunol.</italic>
<volume>120</volume>, <fpage>170</fpage>-<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-5728(01)00421-0</pub-id><pub-id pub-id-type="pmid">11694332</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katayama</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wada</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mizuguchi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hayakawa</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kadowaki</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Nagai</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kamisaki</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Blumberg</surname><given-names>R. S.</given-names></name><etal>et al.</etal></person-group> (<year>2003</year>). <article-title>A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model</article-title>. <source/><italic toggle="yes">Gastroenterology</italic>
<volume>124</volume>, <fpage>1315</fpage>-<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1016/S0016-5085(03)00262-2</pub-id><pub-id pub-id-type="pmid">12730872</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keiser</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Matazel</surname><given-names>K. S.</given-names></name>, <name name-style="western"><surname>Esser</surname><given-names>M. K.</given-names></name>, <name name-style="western"><surname>Feifel</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Prus</surname><given-names>A. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Systemic administration of the neurotensin NTS(1)-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats</article-title>. <source/><italic toggle="yes">Exp. Clin. Psychopharmacol.</italic>
<volume>22</volume>, <fpage>541</fpage>-<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1037/a0037912</pub-id><pub-id pub-id-type="pmid">25222546</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Prenatal lipopolysaccharide induces hypothalamic dopaminergic hypoactivity and autistic-like behaviors: repetitive self-grooming and stereotypies</article-title>. <source/><italic toggle="yes">Behav. Brain Res.</italic>
<volume>331</volume>, <fpage>25</fpage>-<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2017.05.013</pub-id><pub-id pub-id-type="pmid">28526515</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Taricano</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Maiorka</surname><given-names>P. C.</given-names></name>, <name name-style="western"><surname>Palermo-Neto</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name></person-group> (<year>2010a</year>). <article-title>Prenatal lipopolysaccharide reduces social behavior in male offspring</article-title>. <source/><italic toggle="yes">Neuroimmunomodulation</italic>
<volume>17</volume>, <fpage>240</fpage>-<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1159/000290040</pub-id><pub-id pub-id-type="pmid">20203530</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Taricano</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Flório</surname><given-names>J. C.</given-names></name>, <name name-style="western"><surname>Palermo-Neto</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name></person-group> (<year>2010b</year>). <article-title>Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring</article-title>. <source/><italic toggle="yes">Behav. Brain Res.</italic>
<volume>211</volume>, <fpage>77</fpage>-<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2010.03.009</pub-id><pub-id pub-id-type="pmid">20226214</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Chaves-Kirsten</surname><given-names>G. P.</given-names></name>, <name name-style="western"><surname>Chaible</surname><given-names>L. M.</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Martins</surname><given-names>D. O.</given-names></name>, <name name-style="western"><surname>Britto</surname><given-names>L. R. G.</given-names></name>, <name name-style="western"><surname>Dagli</surname><given-names>M. L. Z.</given-names></name>, <name name-style="western"><surname>Torrão</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Palermo-Neto</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Hypoactivity of the central dopaminergic system and autistic-like behavior induced by a single early prenatal exposure to lipopolysaccharide</article-title>. <source/><italic toggle="yes">J. Neurosci. Res.</italic>
<volume>90</volume>, <fpage>1903</fpage>-<lpage>1912</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23089</pub-id><pub-id pub-id-type="pmid">22714803</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Lippi</surname><given-names>L. L.</given-names></name>, <name name-style="western"><surname>Bevilacqua</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name></person-group> (<year>2013</year>). <article-title>LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1β levels in adult rat offspring: relevance to autism</article-title>. <source/><italic toggle="yes">PLoS ONE</italic>
<volume>8</volume>, <fpage>e82244</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0082244</pub-id><pub-id pub-id-type="pmid">24312647</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Chaves-Kirsten</surname><given-names>G. P.</given-names></name>, <name name-style="western"><surname>Bernardes</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Scavone</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sarkis</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name> and <name name-style="western"><surname>Felicio</surname><given-names>L. F.</given-names></name></person-group> (<year>2015a</year>). <article-title>Lipopolysaccharide exposure induces maternal hypozincemia, and prenatal zinc treatment prevents autistic-like behaviors and disturbances in the striatal dopaminergic and mTOR systems of offspring</article-title>. <source/><italic toggle="yes">PLoS ONE</italic>
<volume>10</volume>, <fpage>e0134565</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0134565</pub-id><pub-id pub-id-type="pmid">26218250</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Queiroz-Hazarbassanov</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name> and <name name-style="western"><surname>Felicio</surname><given-names>L. F.</given-names></name></person-group> (<year>2015b</year>). <article-title>Prenatal zinc prevents communication impairments and BDNF disturbance in a rat model of autism induced by prenatal lipopolysaccharide exposure</article-title>. <source/><italic toggle="yes">Life Sci.</italic>
<volume>130</volume>, <fpage>12</fpage>-<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2015.02.027</pub-id><pub-id pub-id-type="pmid">25817235</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name>, <name name-style="western"><surname>Casarin</surname><given-names>R. C.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name> and <name name-style="western"><surname>Felicio</surname><given-names>L. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway</article-title>. <source/><italic toggle="yes">PLoS ONE</italic>
<volume>13</volume>, <fpage>e0197060</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0197060</pub-id><pub-id pub-id-type="pmid">29791472</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landreth</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease</article-title>. <source/><italic toggle="yes">Exp. Neurol.</italic>
<volume>199</volume>, <fpage>245</fpage>-<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2006.04.006</pub-id><pub-id pub-id-type="pmid">16733054</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landrigan</surname><given-names>P. J.</given-names></name></person-group> (<year>2010</year>). <article-title>What causes autism? Exploring the environmental contribution</article-title>. <source/><italic toggle="yes">Curr. Opin. Pediatr.</italic>
<volume>22</volume>, <fpage>219</fpage>-<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1097/MOP.0b013e328336eb9a</pub-id><pub-id pub-id-type="pmid">20087185</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>H. J.</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>W. W.</given-names></name>, <name name-style="western"><surname>Madsen</surname><given-names>K. M.</given-names></name>, <name name-style="western"><surname>Vestergaard</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Olesen</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Agerbo</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Schendel</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Thorsen</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Mortensen</surname><given-names>P. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status</article-title>. <source/><italic toggle="yes">Am. J. Epidemiol.</italic>
<volume>161</volume>, <fpage>916</fpage>-<lpage>928</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwi123</pub-id><pub-id pub-id-type="pmid">15870155</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chauhan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sheikh</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Patil</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chauhan</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.-M.</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Malik</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Elevated immune response in the brain of autistic patients</article-title>. <source/><italic toggle="yes">J. Neuroimmunol.</italic>
<volume>207</volume>, <fpage>111</fpage>-<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.12.002</pub-id><pub-id pub-id-type="pmid">19157572</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marui</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Funatogawa</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Koishi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hashimoto</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Nanba</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Nishida</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sugiyama</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Kasai</surname><given-names>K.</given-names></name><etal>et al.</etal></person-group> (<year>2007</year>). <article-title>Tachykinin 1 (TAC1) gene SNPs and haplotypes with autism: a case-control study</article-title>. <source/><italic toggle="yes">Brain Dev.</italic>
<volume>29</volume>, <fpage>510</fpage>-<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2007.01.010</pub-id><pub-id pub-id-type="pmid">17376622</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcpheeters</surname><given-names>M. L.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Sathe</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bruzek</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Krishnaswami</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Jerome</surname><given-names>R. N.</given-names></name> and <name name-style="western"><surname>Veenstra-Vanderweele</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>A systematic review of medical treatments for children with autism spectrum disorders</article-title>. <source/><italic toggle="yes">Pediatrics</italic>
<volume>127</volume>, <fpage>e1312</fpage>-<lpage>e1321</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2011-0427</pub-id><pub-id pub-id-type="pmid">21464191</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moraes</surname><given-names>M. M. T.</given-names></name>, <name name-style="western"><surname>Galvão</surname><given-names>M. C.</given-names></name>, <name name-style="western"><surname>Cabral</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Coelho</surname><given-names>C. P.</given-names></name>, <name name-style="western"><surname>Queiroz-Hazarbassanov</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Martins</surname><given-names>M. F. M.</given-names></name>, <name name-style="western"><surname>Bondan</surname><given-names>E. F.</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M. M.</given-names></name> and <name name-style="western"><surname>Kirsten</surname><given-names>T. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Propentofylline prevents sickness behavior and depressive-like behavior induced by lipopolysaccharide in rats via neuroinflammatory pathway</article-title>. <source/><italic toggle="yes">PLoS ONE</italic>
<volume>12</volume>, <fpage>e0169446</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0169446</pub-id><pub-id pub-id-type="pmid">28056040</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muehlmann</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Wolfman</surname><given-names>S. L.</given-names></name> and <name name-style="western"><surname>Devine</surname><given-names>D. P.</given-names></name></person-group> (<year>2018</year>). <article-title>The role of neurotensin in vulnerability for self-injurious behaviour: studies in a rodent model</article-title>. <source/><italic toggle="yes">J. Intellect. Disabil. Res.</italic>
<volume>62</volume>, <fpage>997</fpage>-<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1111/jir.12519</pub-id><pub-id pub-id-type="pmid">30033601</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>K. B.</given-names></name>, <name name-style="western"><surname>Grether</surname><given-names>J. K.</given-names></name>, <name name-style="western"><surname>Croen</surname><given-names>L. A.</given-names></name>, <name name-style="western"><surname>Dambrosia</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Dickens</surname><given-names>B. F.</given-names></name>, <name name-style="western"><surname>Jelliffe</surname><given-names>L. L.</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>R. L.</given-names></name> and <name name-style="western"><surname>Phillips</surname><given-names>T. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation</article-title>. <source/><italic toggle="yes">Ann. Neurol.</italic>
<volume>49</volume>, <fpage>597</fpage>-<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1002/ana.1024</pub-id><pub-id pub-id-type="pmid">11357950</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.-W.</given-names></name>, <name name-style="western"><surname>Yi</surname><given-names>J.-H.</given-names></name>, <name name-style="western"><surname>Miranpuri</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Satriotomo</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Bowen</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Resnick</surname><given-names>D. K.</given-names></name> and <name name-style="western"><surname>Vemuganti</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats</article-title>. <source/><italic toggle="yes">J. Pharmacol. Exp. Ther.</italic>
<volume>320</volume>, <fpage>1002</fpage>-<lpage>1012</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.106.113472</pub-id><pub-id pub-id-type="pmid">17167171</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A. B.</given-names></name>, <name name-style="western"><surname>Tsilioni</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Leeman</surname><given-names>S. E.</given-names></name> and <name name-style="western"><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism</article-title>. <source/><italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic>
<volume>113</volume>, <fpage>E7049</fpage>-<lpage>E7E58</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1604992113</pub-id><pub-id pub-id-type="pmid">27663735</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posar</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Visconti</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Autism in 2016: the need for answers</article-title>. <source/><italic toggle="yes">J. Pediatr.</italic>
<volume>93</volume>, <fpage>111</fpage>-<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.jped.2016.09.002</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prakash</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer's disease</article-title>. <source/><italic toggle="yes">Neurotox. Res.</italic>
<volume>25</volume>, <fpage>335</fpage>-<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-013-9437-9</pub-id><pub-id pub-id-type="pmid">24277156</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quattrocki</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Friston</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Autism, oxytocin and interoception</article-title>. <source/><italic toggle="yes">Neurosci. Biobehav. Rev.</italic>
<volume>47</volume>, <fpage>410</fpage>-<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.09.012</pub-id><pub-id pub-id-type="pmid">25277283</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Comparing rat's to human's age: how old is my rat in people years?</article-title>
<source/><italic toggle="yes">Nutrition</italic>
<volume>21</volume>, <fpage>775</fpage>-<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2005.04.002</pub-id><pub-id pub-id-type="pmid">15925305</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricci</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Businaro</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ippoliti</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Lo Vasco</surname><given-names>V. R.</given-names></name>, <name name-style="western"><surname>Massoni</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Onofri</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Troili</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Pontecorvi</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Morelli</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rapp Ricciardi</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>). <article-title>Altered cytokine and BDNF levels in autism spectrum disorder</article-title>. <source/><italic toggle="yes">Neurotox. Res.</italic>
<volume>24</volume>, <fpage>491</fpage>-<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-013-9393-4</pub-id><pub-id pub-id-type="pmid">23604965</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodríguez De Lores Arnaiz</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Antonelli</surname><given-names>M. C.</given-names></name></person-group> (<year>2016</year>). <article-title>In search of concomitant alterations of dopaminergic and neurotensinergic systems in stress conditions</article-title>. <source/><italic toggle="yes">Neurochem. Res.</italic>
<volume>41</volume>, <fpage>423</fpage>-<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-016-1849-5</pub-id><pub-id pub-id-type="pmid">26869038</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theoharides</surname><given-names>T. C.</given-names></name>, <name name-style="western"><surname>Kempuraj</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Redwood</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Autism: an emerging ‘neuroimmune disorder’ in search of therapy</article-title>. <source/><italic toggle="yes">Expert Opin Pharmacother.</italic>
<volume>10</volume>, <fpage>2127</fpage>-<lpage>2143</lpage>. <pub-id pub-id-type="doi">10.1517/14656560903107789</pub-id><pub-id pub-id-type="pmid">19640207</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tordjman</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Botbol</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Brailly-Tabard</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Perez-Diaz</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Graignic</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Carlier</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Schmit</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rolland</surname><given-names>A.-C.</given-names></name>, <name name-style="western"><surname>Bonnot</surname><given-names>O.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>). <article-title>Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder</article-title>. <source/><italic toggle="yes">PLoS ONE</italic>
<volume>4</volume>, <fpage>e5289</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005289</pub-id><pub-id pub-id-type="pmid">19707566</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tordjman</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Somogyi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Coulon</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kermarrec</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Bronsard</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Bonnot</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Weismann-Arcache</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Botbol</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lauth</surname><given-names>B.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>). <article-title>Gene x Environment interactions in autism spectrum disorders: role of epigenetic mechanisms</article-title>. <source/><italic toggle="yes">Front. Psychiatry</italic>
<volume>5</volume>, <fpage>53</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00053</pub-id><pub-id pub-id-type="pmid">25136320</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsilioni</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Dodman</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Petra</surname><given-names>A. I.</given-names></name>, <name name-style="western"><surname>Taliou</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Francis</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Moon-Fanelli</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Shuster</surname><given-names>L.</given-names></name> and <name name-style="western"><surname>Theoharides</surname><given-names>T. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism</article-title>. <source/><italic toggle="yes">Transl. Psychiatry</italic>
<volume>4</volume>, <fpage>e466</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.106</pub-id><pub-id pub-id-type="pmid">25313509</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urakubo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Jarskog</surname><given-names>L. F.</given-names></name>, <name name-style="western"><surname>Lieberman</surname><given-names>J. A.</given-names></name> and <name name-style="western"><surname>Gilmore</surname><given-names>J. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain</article-title>. <source/><italic toggle="yes">Schizophr. Res.</italic>
<volume>47</volume>, <fpage>27</fpage>-<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/S0920-9964(00)00032-3</pub-id><pub-id pub-id-type="pmid">11163542</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>J.-P.</given-names></name>, <name name-style="western"><surname>Mazella</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Kitabgi</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Neurotensin and neurotensin receptors</article-title>. <source/><italic toggle="yes">Trends Pharmacol. Sci.</italic>
<volume>20</volume>, <fpage>302</fpage>-<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-6147(99)01357-7</pub-id><pub-id pub-id-type="pmid">10390649</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weizman</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Gil-Ad</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Dick</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tyano</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Szekely</surname><given-names>G. A.</given-names></name> and <name name-style="western"><surname>Laron</surname><given-names>Z.</given-names></name></person-group> (<year>1988</year>). <article-title>Low plasma immunoreactive beta-endorphin levels in autism</article-title>. <source/><italic toggle="yes">J. Am. Acad. Child Adolesc. Psychiatry</italic>
<volume>27</volume>, <fpage>430</fpage>-<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1097/00004583-198807000-00009</pub-id><pub-id pub-id-type="pmid">2972691</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wink</surname><given-names>L. K.</given-names></name>, <name name-style="western"><surname>Plawecki</surname><given-names>M. H.</given-names></name>, <name name-style="western"><surname>Erickson</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Stigler</surname><given-names>K. A.</given-names></name> and <name name-style="western"><surname>Mcdougle</surname><given-names>C. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Emerging drugs for the treatment of symptoms associated with autism spectrum disorders</article-title>. <source/><italic toggle="yes">Expert Opin Emerg. Drugs</italic>
<volume>15</volume>, <fpage>481</fpage>-<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1517/14728214.2010.487860</pub-id><pub-id pub-id-type="pmid">20470188</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Cilz</surname><given-names>N. I.</given-names></name>, <name name-style="western"><surname>Kurada</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wada</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Combs</surname><given-names>C. K.</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Lesage</surname><given-names>F.</given-names></name> and <name name-style="western"><surname>Lei</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer's disease model</article-title>. <source/><italic toggle="yes">J. Neurosci.</italic>
<volume>34</volume>, <fpage>7027</fpage>-<lpage>7042</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0408-14.2014</pub-id><pub-id pub-id-type="pmid">24828655</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamanaka</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Itakura</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tsuchida</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Noguchi</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Taiji</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice</article-title>. <source/><italic toggle="yes">Diabetes Obes. Metab.</italic>
<volume>9</volume>, <fpage>879</fpage>-<lpage>888</lpage>. <pub-id pub-id-type="doi">10.1111/j.1463-1326.2006.00675.x</pub-id><pub-id pub-id-type="pmid">17924870</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Serum oxytocin levels and an oxytocin receptor gene polymorphism (rs2254298) indicate social deficits in children and adolescents with autism spectrum disorders</article-title>. <source/><italic toggle="yes">Front. Neurosci.</italic>
<volume>11</volume>, <fpage>221</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2017.00221</pub-id><pub-id pub-id-type="pmid">28484366</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.-L.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>A.-P.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C.-F.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>L.-Z.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.-Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Qin</surname><given-names>Z.-H.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway</article-title>. <source/><italic toggle="yes">Neuroscience</italic>
<volume>176</volume>, <fpage>381</fpage>-<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.12.029</pub-id><pub-id pub-id-type="pmid">21185913</pub-id></mixed-citation>
</ref>
<ref id="BIO041327C67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.-F.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y.-C.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>M.-X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.-S.</given-names></name>, <name name-style="western"><surname>Shou</surname><given-names>X.-J.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>S.-P.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name> and <name name-style="western"><surname>Han</surname><given-names>J.-S.</given-names></name></person-group> (<year>2016</year>). <article-title>Plasma oxytocin and arginine-vasopressin levels in children with autism spectrum disorder in china: associations with symptoms</article-title>. <source/><italic toggle="yes">Neurosci. Bull.</italic>
<volume>32</volume>, <fpage>423</fpage>-<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1007/s12264-016-0046-5</pub-id><pub-id pub-id-type="pmid">27342432</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>